Colestilan chloride is under clinical development by Mitsubishi Tanabe Pharma and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Colestilan chloride’s likelihood of approval (LoA) and phase transition for Functional (Non Ulcer) Dyspepsia took place on 28 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Colestilan chloride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Colestilan chloride overview

Colestilan chloride (MCI-196, colestilan, colestimide, Cholebine, BindRen) is a non-metallic phosphate-binding polymer. Choline and BindRen are formulated as tablets and granules for oral route of administration. Cholebine is used for the treatment of hypercholesterolemia and familial hypercholesterolemia. BindRen is indicated for the treatment of Hyperphosphatemia in adult patients with Chronic Kidney Disease (CKD) Stage 5 receiving haemodialysis or peritoneal dialysis.

The drug candidate is under development for treatment-resistant functional dyspepsia. It was also under development for dyslipidemia, hyperphosphatemia and type II diabetes.

Mitsubishi Tanabe Pharma overview

Mitsubishi Tanabe Pharma (Mitsubishi Tanabe), a subsidiary of Mitsubishi Chemical Holdings Corp, identifies, develops, manufactures, procures, and commercializes ethical drugs and over the counter (OTC) pharmaceutical products. The company develops ethical drugs for autoimmune disease, diabetes, kidney diseases, central nervous system (CNS) disorders, and others. It also develops vaccines for preventing various infectious diseases. Mitsubishi Tanabe also offers major products for skin conditions and digestive medicines. The company markets its products to wholesalers, hospitals, clinics, and drugstores. It has subsidiaries in Asia, Europe, and North America. Mitsubishi Tanabe is headquartered in Osaka, Japan.

Quick View Colestilan chloride LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Colestilan chloride
Administration Pathway
  • Oral
Therapeutic Areas
  • Gastrointestinal
  • Metabolic Disorders
  • Nutritional Disorders
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.